MAIA Biotechnology Inc.
(MAIA)
undefined
undefined%
At close: undefined
2.06
4.04%
After-hours Dec 13, 2024, 07:45 PM EST
Company Description
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer.
Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
The company was founded in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology Inc.
| Country | United States |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Vlad Vitoc M.B.A., M.D. |
Contact Details
Address: 444 West Lake Street Chicago, Illinois United States | |
| Website | https://www.MAIABiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer & Chairman of the Board of Directors |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Jeffrey C. Himmelreich | Head of Finance |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | D | Filing |
| Nov 08, 2024 | 8-K | Current Report |
| Nov 07, 2024 | 4 | Filing |
| Nov 05, 2024 | 8-K | Current Report |
| Nov 04, 2024 | 4 | Filing |
| Nov 04, 2024 | 4 | Filing |
| Nov 04, 2024 | 4 | Filing |
| Nov 04, 2024 | 4 | Filing |